BIOSIMILAR CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Biosimilar Contract Manufacturing Market, By Product Type (Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins), By Application (Oncology, Diabetes, Infectious Diseases, Chronic and Autoimmune Disorders, Blood Disorders, and Growth Hormonal Deficiency), By Type (Mammalian Manufacturing and Microbial Manufacturing), By Service Type (Upstream Processing, Downstream Processing, Biosimilarity testing, Bioassay (in vitro/in vivo), Process Development, and Fill & Finish) , By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

The global biosimilar contract manufacturing market possesses strong momentum driven by the increasing development of biosimilars and the need to reduce production costs. As patents of major biologics expire, the demand for lower-cost biosimilars is set to surge in the coming years. This growing demand represents a major opportunity for contract manufacturers to gain new business. North America is expected to dominate the market owing to supportive regulatory guidelines and early acceptance of biosimilars. However, Asian markets like China and India are emerging as fastest growing regions due to increasing biologics manufacturing capabilities and reducing costs in these countries.
While market trends remain very positive, capacity constraints, and heavy investments required for setting up facilities pose challenges to contract manufacturers. Additionally, the complex nature of biosimilar development and regulatory approvals remains a major restraint. Any manufacturing or quality issues can delay projects and impact revenues. Furthermore, intellectual property disputes between innovator companies and biosimilar developers may hamper market growth. Overall, the lucrative prospects of the biosimilars market, coupled with the need to share risks, provide a compelling case for biopharma companies to engage CMOs through the product lifecycle.